PhaseBio

PhaseBio is focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications.

[PhaseBio @PhaseBio]

PhaseBio announces expansion of Phase 3 #REVERSEIT trial for #bentracimab into Canada.

📺Learn how our critical care therapy has potential to help patients taking #ticagrelor who experience spontaneous bleeding or require urgent surgery: https://t.co/QEVj04fJEr. #TakeItToHeart

[PhaseBio @PhaseBio]

This morning we announced our second quarter #earnings results. Read more about our recent highlights and corporate outlook here: https://t.co/yjtIzkHUfT

$PHAS #TakeItToHeart

[PhaseBio @PhaseBio]

This week, we’re spotlighting our CFO, John Sharp, who has 20+ years of experience in financial and business planning. Thanks to his leadership, we continue to advance novel treatments through clinical development for those w/ #cardiovascular disease.

[PhaseBio @PhaseBio]

Our CEO, Jonathan Mow, recently sat down with @biospace's @GailLdutton to discuss our company’s latest momentum & progress around our potential #ticagrelor reversal agent, #bentracimab. Get up to date with their latest #news feature: https://t.co/rgB8gxu6W6

$PHAS #TakeItToHeart

[PhaseBio @PhaseBio]

We'd like to take time to celebrate and thank our entire PhaseBio team whose ongoing commitment & unyielding determination is helping to close the gap between patients w/ #cardiovascular disease and adequate care. Learn more about our talented team today: https://t.co/SPgMjKaqlZ

[PhaseBio @PhaseBio]

At PhaseBio, we believe maintaining a collaborative & teamwork-driven environment is critical when it comes to developing new, innovative therapies for patients with #cardiovascular disease. Learn more about our mission and #corevalues here: https://t.co/ibHRvlf6iS

[PhaseBio @PhaseBio]

In recognition of #StrokeMonth, our CMO John Lee, M.D., Ph.D., shared thoughts on the importance of being prepared for #stroke and reacting quickly to this life-threatening event. Tune into his message of support here:

@American_Stroke

[PhaseBio @PhaseBio]

We’ve recently reported our #financial and #business updates for the first quarter of 2022. Catch up on some of our company’s latest #corporate news, #milestones and our future outlook now: https://t.co/PiMtgM1Bx2

$PHAS #TakeItToHeart

[PhaseBio @PhaseBio]

Corporate #news update: Our company recently met with the U.S. #FDA to discuss our clinical #data for our lead program #bentracimab. Learn more about this exciting milestone and what it means for the therapy’s potential future in the U.S.: https://t.co/PPfglMfw1S

[PhaseBio @PhaseBio]

May is National Stroke Awareness Month, and an important time to remember the warning signs for #stroke. By doing so, you could potentially save a loved one or better assist in their recovery. More resources are available at @American_Stroke: https://t.co/78dnSB181H

#StrokeMonth

[PhaseBio @PhaseBio]

#DYK: In the United States, every 36 seconds one person loses their life to cardiovascular disease. Learn how we’re working to slow down the clock with our pipeline of novel #cardiovascular therapeutic candidates: https://t.co/xHdRNiIRiR
#TakeItToHeart #CVD

[PhaseBio @PhaseBio]

At PhaseBio, five core values drive our ongoing work in cardiovascular disease, which is anchored by our focus on patients. Learn more about our commitment to using compelling & innovative science to positively impact patients & clinicians in the space: https://t.co/WbMHR6WeRz

[PhaseBio @PhaseBio]

#ICYMI: This week, our CFO John Sharp participated in a #fireside chat at the 21st Annual Needham Healthcare Conference. Find more details & learn how you can tune in here: https://t.co/TgYZQ0MCSr

$PHAS #TakeItToHeart

[PhaseBio @PhaseBio]

In case you missed it, we presented positive results from our completed Phase 2b trial for #bentracimab on April 2nd at the 2022 @ACCinTouch 71st Annual Scientific Session. Learn more about the data here: https://t.co/qN8ZVoMOlX. #ACC22 $PHAS

[PhaseBio @PhaseBio]

Today marks #WorldHealthDay! Visit @WHO to learn more about this #global initiative and steps we can take to keep humans and the planet healthy: https://t.co/w3xh6rvgYg

#TakeItToHeart #HealthierTomorrow #WorldHealthDay2022

[Medscape Education @MedscapeCME]

Learn about the latest advances in antiplatelet reversal and clinical implications to optimize patient outcomes. #CME
https://t.co/eXxOnJnL29

[PhaseBio @PhaseBio]

We're on a mission to meet the growing demand for more effective treatments to counteract #cardiovascular and #heart diseases. As we close out American #HeartMonth, our CEO Jonathan Mow discusses PhaseBio’s actions to bring innovation to #CVD communities:

#TakeItToHeart

[PhaseBio @PhaseBio]

#DYK: #cardiovascular disease is the #1 killer of #women in the U.S., causing 1 in 5 deaths each year. Learn more about #heartdisease including the warning signs & symptoms of a #heartattack & #stroke and ways to prioritize your overall #health.

#OurHearts #AmericanHeartMonth

[PhaseBio @PhaseBio]

We’re excited to announce we’ll be presenting #data from our Phase 2b trial of #bentracimab in a late-breaking session at the @ACCinTouch Annual Scientific Session & Expo this April. Details on our presentation here: https://t.co/up5ox0S3py

$PHAS #TakeItToHeart #ACC22

[PhaseBio @PhaseBio]

We’re wearing red to help raise #awareness about the increasing risk of #heartdisease & #stroke among women in the U.S. Check out additional #advocacy & support tools to spread awareness about #hearthealth from the @American_Heart: https://t.co/SKwu87c5Jr
#NationalWearRedDay